Shares of Biogen Inc. BIIB advanced 2.06% to $118.89 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 2.51% to 5,287.76 and ...

Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

U.S. pharma imports hit $200 billion in 2024, a 10% tariff could cost the sector $20 billion. Vertex and Alnylam are seen as most resilient to tariff, tax and Medicaid risks. Markets are messy ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Biogen recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, despite these ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080 ...

Investors can allege presumption of reliance now, judge said Clinical trial data claim revived after appeals court trip Biogen Inc. investors can advance their claim that the company misrepresented ...

Kisunla, along with two approved Alzheimer’s therapies from partners Biogen and Eisai, is part of a class of drugs that can also cause side effects like swelling and small-scale bleeding in the brain.

Discover the top 10 gaming logos of all time! Explore iconic designs that shaped the gaming industry and learn what makes them unforgettable. Most people think gaming is just entertainment. They're ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...